Do Chemically Modified Oligonucleotide Therapeutics Require Environmental Risk Assessment?
Environmental Science & Technology · 18.08.2026 · 60 (32) · 22174-22185
DOI: 10.1021/acs.est.6c05885 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Science & Technology, online erschienen am 05.08.2026. Verfasst von Thomas B Hofstetter und 5 weiteren Autor:innen. Beteiligte Einrichtung: Eawag, Swiss Federal Institute of Aquatic Science and Technology, 8600Dübendorf, Switzerland. Hauptthemen laut MEDLINE: Oligonucleotides. Die Arbeit nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss Federal Office for the Environment.
Abstract (Originalsprache)
Synthetic modified oligonucleotides (mONs) are a rapidly evolving class of nucleic acid–based therapeutics with an expected increase in market approval rates. mONs are designed to resist enzymatic degradation in patients, and their biological effects arise from chemical modifications and sequence-dependent phenomena comparable to those of biologically active genetic materials. These properties and the absence of experimental evidence on the occurrence and impact of mONs emitted into aquatic environments raise questions about the need for environmental risk assessment (ERA). Here, we evaluate (i) the chemical modifications proposed for mONs and found in approved therapeutics, (ii) pharmacological data on excretion to inform emission scenarios, (iii) analytical approaches for quantification of mONs in environmental matrices, (iv) anticipated distribution and transformation processes, and (v) potential (eco)toxicological effect profiles of mONs. We propose that focusing on chemical modifications allows for a more generalized approach to assessing mON exposure in engineered and natural aquatic systems. By contrast, the evaluation of effects requires case-by-case studies of chemical modifications and nucleotide sequences in the mON products. We suggest to address the need for ERAs by monitoring mONs in wastewater with newly developed analytical methods as well as experimental studies in laboratory model systems of processes that determine mON exposure and effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eawag, Swiss Federal Institute of Aquatic Science and Technology, 8600Dübendorf, Switzerland.
- Institute of Biogeochemistry and Pollutant Dynamics (IBP), ETH Zürich, 8092Zürich, Switzerland.
- University of Colorado Boulder, Department of Civil, Environmental, and Architectural Engineering and Environmental Engineering Program, Boulder, Colorado80309, United States.
- Eawag, Swiss Federal Institute of Aquatic Science and Technology, 6047Kastanienbaum, Switzerland.
ORCID-Profile: Thomas B Hofstetter, Cresten Mansfeldt, Serina L Robinson, Michael Sander, Helmut Bürgmann
Förderung
- Swiss Federal Office for the Environment
Zitieren
APA
Hofstetter, T. B., Scheidat, I., Mansfeldt, C., Robinson, S. L., Sander, M., & Bürgmann, H. (2026). Do Chemically Modified Oligonucleotide Therapeutics Require Environmental Risk Assessment?. Environmental Science & Technology, 60(32), 22174-22185. https://doi.org/10.1021/acs.est.6c05885
Vancouver
Hofstetter TB, Scheidat I, Mansfeldt C, Robinson SL, Sander M, Bürgmann H. Do Chemically Modified Oligonucleotide Therapeutics Require Environmental Risk Assessment?. Environmental Science & Technology. 2026;60(32):22174-22185. doi:10.1021/acs.est.6c05885
BibTeX
@article{Hofstetter2026,
author = {Hofstetter, Thomas B and Scheidat, Inga and Mansfeldt, Cresten and Robinson, Serina L and Sander, Michael and Bürgmann, Helmut},
title = {Do Chemically Modified Oligonucleotide Therapeutics Require Environmental Risk Assessment?},
journal = {Environmental Science & Technology},
year = {2026},
volume = {60},
number = {32},
pages = {22174--22185},
doi = {10.1021/acs.est.6c05885}
}
EUVIMED